Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025

Core Viewpoint - Mineralys Therapeutics, Inc. is set to report its third-quarter financial results on November 10, 2025, focusing on its development of medicines targeting hypertension and related comorbidities [1] Company Overview - Mineralys Therapeutics is a clinical-stage biopharmaceutical company based in Radnor, Pennsylvania, specializing in treatments for hypertension and related conditions such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA) [3] - The company's lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor [3] - Mineralys was founded by Catalys Pacific and aims to address diseases driven by dysregulated aldosterone [3] Upcoming Financial Results - The financial results for the third quarter ended September 30, 2025, will be announced after market close on November 10, 2025 [1] - A conference call will be held on the same day at 4:30 p.m. ET, with details provided for both domestic and international participants [2]